12 In December 2025, high-dose oral semaglutide (Wegovy) became the first orally administered GLP-1 RA approved for obesity treatment, providing a noninjectable alternative within the IBT class
Typical daily range: 50100 mg once daily subcutaneously, started low and raised gradually to tolerance over an 812 week course
Contains no artificial colours, preservatives, or sweeteners
The extent to which the mechanisms responsible for this decline are evolutionarily conserved remains unclear
When taken with food, as intended for AllerGzyme, the enzymes dedicate their catalytic energy to breaking down the dietary proteins present in the stomach and GI tract
The results, while modest, were consistent with the peptide's selective mechanism.[4] The peptide appeared especially useful in the study for mobilizing visceral and abdominal fat the type most resistant to traditional diet and exercise